Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
absence, add, adjudicated, Advisory, alive, antineutrophil, attack, BLA, blinded, bound, bring, broad, cardiovascular, choice, cholesterol, civil, CMO, Columbia, committee, companion, comparison, complied, comply, composite, confirmatory, consent, convened, conversion, correlate, costly, counted, criminal, death, defendant, Defense, degradation, diagnostic, discovering, dose, elevated, EMA, emerging, evolve, fashion, fracture, fulfill, fulfilling, furthest, Gaza, Germany, halted, heart, imbalance, Immunex, implicate, imposition, inflammation, interchangeability, Israel, Japan, Kingdom, KRYSTEXXA, larger, length, ligand, lipoprotein, mCRC, median, member, metric, mOS, MRD, nephrology, ODAC, orphan, outweigh, pathway, pediatric, pegloticase, pharmacovigilance, plaintiff, postmenopausal, presence, prevent, prove, publish, quality, reevaluate, regorafenib, rejected, reliably, remanded, renewed, replaced, reputational, residual, revised, revoked, settled, shown, speculate, speculative, sponsored, stack, statistical, statistically, stroke, substance, substudy, successfully, surrogate, TEPEZZA, tipiracil, Tokyo, trifluridine, unaffordable, unified, unrelated, UPLIZNA, verification, voted, warning, women
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view